Q3 25 EPS
$0.15
BEAT +30.43%
Est. $0.12
Q3 25 Revenue
$138.7M
BEAT +0.34%
Est. $138.2M
vs S&P Since Q3 25
+11.6%
BEATING MARKET
BVS +19.9% vs S&P +8.3%
Market Reaction
Did BVS Beat Earnings? Q3 2025 Results
Bioventus posted a convincing earnings beat in Q3 2025, with non-GAAP EPS of $0.15 clearing the $0.12 consensus by 30.43% and revenue of $138.65 million edging past estimates by 0.34%, even as reported sales slipped 0.2% year-over-year following the … Read more Bioventus posted a convincing earnings beat in Q3 2025, with non-GAAP EPS of $0.15 clearing the $0.12 consensus by 30.43% and revenue of $138.65 million edging past estimates by 0.34%, even as reported sales slipped 0.2% year-over-year following the divestiture of its Advanced Rehabilitation Business at the end of 2024. The headline revenue figure understates the underlying momentum; organic growth came in at 8.2%, with Pain Treatments rising 6.4% to $67.18 million on strong U.S. Demand for Durolane and Surgical Solutions climbing 9.3% to $50.17 million behind bone graft substitutes and ultrasonics. Profitability improved sharply, with GAAP operating income reaching $11.25 million versus $3.65 million a year ago and Adjusted EBITDA expanding 12.9% to $26.60 million, while the company's new $300.00 million credit agreement lowered interest costs and extended its runway to July 2030. Some observers have flagged the quarter's $17.3 million one-time loss as a consideration for evaluating earnings quality, though management reaffirmed its full-year guidance of $560.00 million to $570.00 million in net sales and Non-GAAP EPS of $0.64 to $0.68, representing growth of 30.6% to 38.8%.
Key Takeaways
- • Above-market organic revenue growth of 8.2% across all three business segments
- • Strong U.S. demand for Durolane single-injection HA therapy
- • Higher demand for Bone Graft Substitutes and Ultrasonics in Surgical Solutions
- • Improved commercial effectiveness and sales force execution with EXOGEN
- • Adjusted EBITDA margin expansion of 220 basis points to 19.2%
- • Lower interest expense from new credit agreement
- • Operating cash flow increased 192% to $30.1 million
BVS YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
BVS Revenue by Segment
With YoY comparisons, source: SEC Filings
BVS Revenue by Geography
With YoY comparisons, source: SEC Filings
“Momentum continued to build across our portfolio as our team delivered an exceptional quarter reflecting above-market organic revenue growth, increased profitability, and significant cash flow acceleration. Looking ahead, we remain committed to delivering on our 2025 objectives, investing in our strategic growth initiatives, and enhancing value for our customers, patients and shareholders.”
— Rob Claypoole, Q3 2025 Earnings Press Release
BVS Earnings Trends
BVS vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BVS EPS Trend
Earnings per share: estimate vs actual
BVS Revenue Trend
Quarterly revenue: estimate vs actual
BVS Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $0.07 | $0.15 | +120.59% | $132.1M | +1.69% |
| Q4 25 BEAT FY | $0.22 | $0.24 | +10.75% | $157.9M | +1.91% |
| FY Full Year | — | $0.68 | — | $568.1M | — |
| Q3 25 BEAT | $0.12 | $0.15 | +30.43% | $138.7M | +0.34% |
| Q2 25 BEAT | $0.20 | $0.21 | +6.76% | $147.7M | +1.23% |
| Q1 25 BEAT | $0.02 | $0.08 | +250.88% | $123.9M | +0.95% |